Propanc Biopharma, Inc.

PPCB

US74346N6022

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 20:36:07 28/05/2024 BST			5-day change	1st Jan Change
0.0012 ^USD	+9.09%		+9.09%	-90.00%

04-16	Propanc Biopharma, Inc. Receives Certificate of Grant for ?Composition of Proenzymes for Cancer Treatment? Patent from European Patent Office	CI
04-16	Propanc Biopharma, Inc. announced that it has received $0.025 million in funding from GS Capital Partners LLC	CI

Propanc Health Group Corporation will Change its Name to Propanc Biopharma Inc

April 07, 2017 at 05:00 am

Effective April 07, 2017, Propanc Health Group Corporation will change its name to Propanc Biopharma Inc.

Latest news about Propanc Biopharma, Inc.

Propanc Biopharma, Inc. Receives Certificate of Grant for ?Composition of Proenzymes for Cancer Treatment? Patent from European Patent Office	04-16	CI
Propanc Biopharma, Inc. announced that it has received $0.025 million in funding from GS Capital Partners LLC	04-15	CI
Propanc Biopharma, Inc. announced that it has received $0.046875 million in funding	02-29	CI
Propanc Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	02-20	CI
Propanc Biopharma Receives Certificate of Grant for PRP Foundation Patent from Canadian Intellectual Property Office	01-16	CI
Propanc Biopharma, Inc. announced that it has received $0.135 million in funding	12-10	CI
Propanc Biopharma, Inc. announced that it has received $0.045 million in funding	12-03	CI
Propanc Biopharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	11-14	CI
Propanc Biopharma, Inc. announced that it has received $0.04 million in funding	28/10/23	CI
Propanc Biopharma, Inc. announced that it expects to receive $0.04 million in funding	19/10/23	CI
Propanc Biopharma, Inc. announced that it has received $0.0575 million in funding from GS Capital Partners LLC	15/10/23	CI
Propanc Biopharma, Inc. announced that it expects to receive $0.0575 million in funding from GS Capital Partners LLC	11/10/23	CI
Propanc Biopharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	28/09/23	CI
Propanc Biopharma, Inc. announced that it has received $0.055 million in funding	30/08/23	CI
Propanc Biopharma, Inc. announced that it has received $0.12 million in funding	29/08/23	CI
Propanc Biopharma, Inc. announced that it has received $0.0725 million in funding from GS Capital Partners LLC	22/08/23	CI
Propanc Biopharma, Inc. announced that it expects to receive $0.055 million in funding	15/08/23	CI
Propanc Biopharma Targets Site of First-In-Human Study for PRP at the Peter Mac Cancer Center, Melbourne, Australia	15/08/23	CI
Propanc Biopharma, Inc. announced that it expects to receive $0.12 million in funding	14/08/23	CI
Propanc Biopharma, Inc. announced that it has received $0.045 million in funding	14/08/23	CI
Propanc Biopharma, Inc. announced that it expects to receive $0.045 million in funding	18/07/23	CI
Propanc Biopharma, Inc. and an Institutional Investor Enters into a Loan Agreement	12/07/23	CI
Propanc Biopharma, Inc. announced that it has received $0.065 million in funding	05/07/23	CI
Propanc Biopharma, Inc. Produces Synthetic Recombinant Proenzymes for Cancer Therapy Targeting Advanced Solid Tumors	05/07/23	CI
Propanc Biopharma, Inc. announced that it expects to receive $0.065 million in funding	28/06/23	CI

Propanc Biopharma, Inc. is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on the development of cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. The Company has developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its lead product candidate, PRP, is a variation upon its formulation and involves pro-enzymes, the inactive precursors of enzymes. PRP is a long-term therapy based on a pancreatic proenzyme formulation to prevent tumor recurrence and metastasis. PRP is a patented, formulation consisting of two proenzymes mixed in a synergetic ratio. PRP is in the preclinical phase of development.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PROPANC BIOPHARMA, INC.	-90.00%	185K
ELI LILLY AND COMPANY	+38.59%	727B
JOHNSON & JOHNSON	-7.89%	354B
MERCK & CO., INC.	+15.66%	328B
ABBVIE INC.	+0.24%	277B
ASTRAZENECA PLC	+13.47%	243B
NOVARTIS AG	+7.35%	205B
ROCHE HOLDING AG	-6.42%	203B
AMGEN INC.	+4.23%	164B
PFIZER, INC.	-1.70%	164B